United StatesOwnership & classification
Founded: 2015
Ownership
STAT (also STAT News) is a US health, medicine and life-sciences news site launched on 4 November 2015 by John W. Henry, owner of The Boston Globe. It is produced by Boston Globe Media Partners and run as a separate brand. Ownership traces to John Henry, the billionaire businessman who bought the Globe in 2013.
Funding
Initially free, STAT has since built a paywalled subscription business (STAT+) alongside advertising, sponsored events and conferences, financed within the privately held Boston Globe Media group. It is a commercial, for-profit operation.
Affiliation & stance
STAT has no party, state or church ties and operates as an independent commercial newsroom focused on health and biotech, owned privately by John Henry's Boston Globe Media. Because it is privately and commercially owned with no party or government control, it is classified INDEPENDENT (matching the site's existing guess).
Editorial lean
- Our estimate
- Center
- Measured from coverage
- Centerbased on 205
74/100
Factual
70/100
Objective
231
Articles
231
reports
Factual: How accurately its articles report the facts, judged against primary sources and the cross-outlet consensus. Only articles that cite their sources are counted.
Objective: How neutral the writing is — whether reporting keeps the writer’s own preferences and opinions out of the article.
Recent coverage
Women in pink rally in support of Lindsay Clancy who is on trial for killing 3 children
Hundreds of supporters, many wearing pink, rallied outside the courthouse where Lindsay Clancy is on trial for the murders of her three children. The group, consisting of women and a few men, expressed solidarity with Clancy, emphasizing the need for greater awareness and understanding of postpartum psychosis, a rare mental illness linked to childbirth. Clancy's legal team acknowledges the deaths but argues she should not face criminal responsibility due to her mental state. Prosecutors claim she planned the January 24, 2023, killings and manipulated her husband's absence. The rally marked the first significant showing of public support during the ongoing trial. Advocates highlighted the lack of recognition and support for women's mental health issues, with participants expressing fear of being dismissed when seeking help.
'Innovation is now part of war fighting'
U.S. military leaders, including Army Lt. Gen. John L. Rafferty and U.S. Space Force Gen. Michael Guetlein, emphasized the critical role of technological innovation in modern warfare. Rafferty highlighted the challenges posed by rapid advancements in missile and asymmetric threats from countries like Iran, Russia, China, and North Korea, stressing the need for continuous adaptation. He noted the importance of integrating AI into defense systems and drew parallels between current conflicts in Ukraine and the Middle East, where innovation has become essential for battlefield success. Rafferty praised Ukraine's integration of military industry with frontline troops and linked these developments to the U.S.'s push for advanced missile defense strategies. Guetlein echoed these concerns, citing the growing conventional weapon capabilities of adversaries as a pressing threat.
STAT+: HHS document offers new clues to Kennedy’s vaccine plans
A Federal Register request for information published by the Department of Health and Human Services (HHS) provides insight into potential changes to U.S. childhood vaccination policies under President Donald Trump and Health Secretary Robert F. Kennedy Jr. The document seeks public input on various aspects of vaccine recommendations, including the possibility of creating new categories beyond the current framework of universal recommendations, risk-based group recommendations, and shared clinical decision-making models. While the request does not implement any changes itself, it signals that altering the existing vaccine policy is a priority for the administration. The public has been given 30 days to submit comments.
Talks on launch of clinical trial of Ebola vaccine in DRC advance, WHO says
Discussions are ongoing between the Democratic Republic of the Congo (DRC) authorities and the World Health Organization (WHO) to accelerate the initiation of a Phase 3 clinical trial for Merck’s Ervebo vaccine, aimed at combating the Bundibugyo strain of Ebola in the northeastern DRC. WHO Director-General Tedros Adhanom Ghebreyesus noted that the current outbreak is the second-largest on record and growing rapidly. While the vaccine targets the Zaire strain, recent studies suggest it might offer cross-protection against Bundibugyo. The WHO recommends including Ervebo in the trial, which would involve randomly assigning participants to receive the vaccine or a placebo. The trial will not use the 'ring vaccination' method used in the successful Ebola Ça Suffit trial in Guinea, opting instead for individual randomization based on findings from subsequent trials. Over 4,500 cases have been confirmed in the DRC, with over 2,060 deaths.
STAT+: Up and down the ladder: The latest comings and goings
The article highlights recent personnel changes at Spruce Biosciences, where Adrian Quartel has been appointed as chief medical officer. Quartel previously served in the same role at Zevra Therapeutics. The piece is part of a recurring feature in which the author, Ed Silverman, shares updates on hiring and promotions within the pharmaceutical industry. The article is presented as an exclusive story available to STAT+ subscribers, emphasizing the importance of such updates in tracking professional movements within the sector.
STAT+: Pharmalittle: We’re reading about a big Roche investment in the U.S., estrogen patch shortages, and more
The article discusses several health-related topics. It mentions a significant investment by Roche in the U.S., highlighting potential implications for healthcare innovation. It also covers the shortage of estrogen patches due to increased demand following changes in FDA labeling guidelines, which led to a surge in prescriptions. The production challenges of these patches, including their complexity and longer manufacturing times compared to traditional pills, contribute to the supply issues. Additionally, the piece references Heidi Overton's nomination for the FDA leadership role under President Trump, noting potential political hurdles in her Senate confirmation process.
STAT+: Are cancer patients getting too much drug?
The article discusses concerns that cancer patients might be receiving unnecessarily high doses and prolonged treatment regimens of costly medications. It mentions Moderna's fluctuating stock performance due to profit-taking and references other biotech news covered in 'The Readout' newsletter. However, the main content of the article is behind a paywall and requires subscription to STAT+ for full access.
Opinion: Lil Nas X’s bipolar diagnosis and the paradox of treatment
Lil Nas X recently revealed his bipolar disorder diagnosis, highlighting a common struggle among high achievers who resist treatment due to fears of losing their creative edge or ambition. The article explores the cultural narrative that equates intense emotion and instability with artistic or professional success, while contrasting this with scientific findings showing that delayed treatment leads to poorer outcomes, including higher suicide risk, substance abuse, and reduced quality of life. Studies cited include a 2025 systematic review in The British Journal of Psychiatry and a 2023 analysis in the Journal of Patient-Reported Outcomes, both emphasizing the negative impacts of untreated bipolar disorder on personal and societal levels.
Focal therapy for localized prostate cancer has divided physicians. Will new data change minds?
Focal therapy for localized prostate cancer has sparked debate among medical professionals due to its potential to minimize the severe side effects associated with traditional treatments such as surgery or radiation. This approach focuses on targeting specific cancerous areas identified through MRI scans, using techniques like heating, freezing, burning, or electrocution to destroy cancer cells. Although focal therapy has been available since the late 1990s, growing interest has emerged alongside advancements in MRI technology. Recent research suggests that focal therapy could yield survival rates similar to conventional treatments, with fewer side effects and greater patient satisfaction. However, the American Urological Association considers it experimental and recommends it only within clinical studies. Despite this, many leading cancer centers and individual doctors provide focal therapy, which is often not covered by commercial insurance.
Opinion: A cure for HIV would be a triumph. But it shouldn’t harm survivors
The article discusses concerns about the potential impact of an HIV cure on long-term survivors who rely on government and nonprofit benefits. It highlights that while advances in HIV cure research are promising, there is a fear that a cure could lead to the loss of critical support services for those who have lived with HIV for decades. These services include Medicaid, Medicare, the Ryan White HIV/AIDS Program, and others. The piece emphasizes the need for policymakers to address the social and administrative challenges that could arise if a cure leads to the discontinuation of these essential benefits. It references specific cases and research to illustrate the complexity of balancing medical progress with the needs of vulnerable populations.
STAT+: How a Trump loyalist got the FDA nomination
The article discusses how the Trump administration sought to secure a permanent appointment for the acting FDA commissioner, Kyle Diamantas, but he declined. As a result, they selected Heidi Overton for the position. The piece highlights the political maneuvering involved in the selection process, focusing on the influence of Trump loyalists within the FDA nomination.
STAT+: FDA approves Ultragenyx gene therapy
The article discusses various topics in biotechnology, including potential advancements in cancer vaccines by Merck and Moderna, recent FDA approvals, and updates on the new FDA commissioner nominee. It also mentions ongoing research on brain organoids that have remained viable for five years in a Harvard laboratory. The piece includes a humorous and speculative remark about the ethical implications of such research.
Contrasting legal decisions on gender-affirming care
The article covers multiple topics related to health and medicine, including updates on cancer research, changes in fundraising practices by the American Cancer Society, the nomination of Heidi Overton to lead the FDA, and the use of AI in healthcare settings. It begins with a brief mention of a cancer vaccine development and a story about the cancellation of a wine-related fundraiser by the American Cancer Society due to conflicts of interest. It then shifts focus to discuss Heidi Overton's role in health policy and her potential impact at the FDA. Finally, it explores the practical applications and limitations of AI chatbots in hospital settings.